🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk CagriSema Phase 3 results — need advice

Novo Nordisk CagriSema Phase 3 results — need advice

mike_mod Tue, Nov 18, 2025 at 8:31 PM 43 replies 1,982 viewsPage 1 of 9
This thread is more than 6 months old. Information may be outdated. Consider searching for more recent discussions.
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 18, 2025 at 8:31 PM#1

Looking at the combination against simply going higher on a single agent, and the price difference is doing more work in my thinking than the mechanism is.

The bit I cannot resolve on my own is whether the amylin component adds anything beyond what a higher GLP-1 dose would achieve.

Not looking for reassurance. Looking for the part I have got wrong.

14 9PharmHunterJen, TomTeleRx, DoseLogDan and 11 others
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Nov 18, 2025 at 8:38 PM#2

Taking the question as asked, rather than the general version of it. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Ask again with the specifics and you will get a better answer than this one.

13 8ZaraB_AL, JakeSmashed95, NauseaFreeNow and 10 others
Reply Quote Save Share Report
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Nov 18, 2025 at 8:45 PM#3
amsterdam_pete said:
The gap between trial results and real-world results is consistent and it is not fraud.

Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.

Last edited: Nov 18, 2025 at 11:45 PM
12 7MikeFit_NJ, InsuranceTom, WendyG_ATL and 9 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Nov 18, 2025 at 8:52 PM#4
mike_mod said:
Looking at the combination against simply going higher on a single agent, and the price difference is doing more work in my thinking than the…

Same experience, arrived at from the opposite direction. Posting only so the count is not one.

11 6TomTeleRx, DoseLogDan, SleepFixSam and 8 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Nov 18, 2025 at 9:27 PM#5

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

Last edited: Nov 18, 2025 at 11:27 PM
10 5GenomicsKate, Dr.ObesityMed, HealthEcon_DC and 7 others
Reply Quote Save Share Report
1239

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register